Aimmune Becomes Point Pharmaceutical Business for Nestlé

In August, Nestlé gobbled up Aimmune in a $2.6 billion deal, and now the food allergy-focused company will serve as the point pharmaceutical business for Nestlé Health Science.

The new global business expands Nestlé Health Science’s growth strategy to span a breadth of offerings with a pharmaceutical business added to its medical nutrition and consumer care offerings. Aimmune brings pharmaceutical expertise and infrastructure to further strengthen and complement Nestle Health Science’s existing focus on the science of nutrition, and the holistic approach to treating food allergies and other food-mediated conditions.